Global Supplier and Leading Enterprise of Scarce Anticancer APIs
Company Profile
Marvel Yijun Biotech Ltd. is dedicated to becoming the largest full-industry-chain enterprise of Taxus x media in Asia, a leading global supplier of scarce anticancer raw materials, and a builder of a digital-intelligent traditional Chinese medicine platform. After three decades of deep cultivation and development, Marvel Yijun has successfully built a super industrial closed loop of "global resource supply + international capital positioning + local market monetization + digital-intelligent ecosystem empowerment", taking the safeguard of human life and health as its mission.
Core Strengths and Resource Moat
Marvel Yijun possesses a strong industrial chain foundation, owning 70,000-mu Taxus media plantation bases and mastery of purification technology achieving an ultra-high purity of 99.91% for active pharmaceutical ingredients (APIs). The company focuses on producing natural paclitaxel, renowned as a "universal" broad-spectrum anticancer agent, and aims to capture over 70% of the global natural paclitaxel API market, thereby securing an absolute dominant position in the supply of core anticancer raw materials.
Corporate Structure
Strategic Vision and Industrial Upgrading
Looking ahead, Marvel Yijun is driving a leap from the US$190 million "raw material track" to the ten-billion-dollar "formulation + service track". With the ultimate vision of building a "Global Paclitaxel Industry Operating System (Taxol Industry OS)", the company is actively extending into high-end paclitaxel injections and digital-intelligent traditional Chinese medicine platforms. By establishing a three-tier technological moat encompassing "purification technology - formulation innovation - AI-assisted diagnosis and treatment", Marvel Yijun will fully achieve global pricing dominance and standard-setting across the paclitaxel industry chain, through three major strategies of digitalization, platformization, and ecosystemization.
Strong Background in Paclitaxel Business
Marvel Yijun is strategically aligned with the long-term vision of its holding company EJUN (Shanghai) Biotechnology Limited who has been in the industry since 1996. EJUN's main business is the entire industry chain of Taxus x media, encompassing the cultivation and planting of Taxus x media, the bio-extraction of paclitaxel, and the sale of paclitaxel raw materials, including paclitaxel injections. It is a comprehensive enterprise controlling the entire Taxus x media industry chain in China.
For more details, please visit their official website:
Marvel Yijun Biotech Limited
Email: info@marvelyijun.com
Tel: +852 2839 8100
Address: Unit 809, Level 8, Cyberport 5, 100 Cyberport Road, Hong Kong
© 2026 Marvel Yijun. All rights reserved.